{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":2,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":41,"n_cols":5,"rows_kept":41,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[2,4,2,5],[3,2,3,3],[4,2,4,3],[5,2,5,3],[7,2,7,3],[8,2,8,3],[14,2,14,3],[14,4,14,5],[15,2,15,3],[15,4,15,5],[16,2,16,3],[16,4,16,5],[17,2,17,3],[18,2,18,3],[20,2,20,3],[21,2,21,3],[22,2,22,3],[23,2,23,3],[36,2,36,3],[37,2,37,3],[39,2,39,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910697874703321"]
[null,null,"Autore",null,"Ho C. Y (Cho Yen), <1928->"]
[null,null,"Titolo",null,"Thermal conductivity of selected materials . Part 2 [[electronic resource] /] / C. Y. Ho, R. W. Powell and P. E. Liley"]
[null,null,"Pubbl/distr/stampa",null,"Washington, D. C. : , : U.S. Dept. Commerce, National Bureau of Standards, , 1968"]
[null,null,"Descrizione fisica",null,"1 online resource (ix, 146 pages) : illustrations"]
[null,null,"Soggetti",null,"Materials - Thermal properties"]
[{"$nulls":4},"Thermal conductivity"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Note generali","NSRDS-NBS 16."]
[{"$nulls":4},"Title from title screen (viewed on June 1, 2012)."]
[{"$nulls":4},"Includes bibliographical references."]
[{"$nulls":4},"Report prepared under contract at the Thermophysical Properties Research Center, Purdue University."]
[null,"2.","Record Nr.",null,"UNINA9910878983003321"]
[null,null,"Autore",null,"Gemma Akihiko"]
[null,null,"Titolo",null,"Analysis File of Drug-Induced Lung Injury : Expert Opinion for Analysis of Big Data / / by Akihiko Gemma"]
[null,null,"Pubbl/distr/stampa",null,"Singapore : , : Springer Nature Singapore : , : Imprint : Springer, , 2024"]
[null,null,"ISBN",null,"9789819734467"]
[{"$nulls":4},"9789819734450"]
[null,null,"Edizione",null,"[1st ed. 2024.]"]
[null,null,"Descrizione fisica",null,"1 online resource (122 pages)"]
[null,null,"Disciplina",null,"616.2"]
[null,null,"Soggetti",null,"Respiratory organs - Diseases"]
[{"$nulls":4},"Medical genetics"]
[{"$nulls":4},"Diseases - Causes and theories of causation"]
[{"$nulls":4},"Oncology"]
[{"$nulls":4},"Pharmacology"]
[{"$nulls":4},"Genetics - Research"]
[{"$nulls":4},"Pneumology"]
[{"$nulls":4},"Clinical Genetics"]
[{"$nulls":4},"Pathogenesis"]
[{"$nulls":4},"Genetics Research"]
[{"$nulls":4},"Malalties de l'aparell respiratori"]
[{"$nulls":4},"Farmacologia"]
[{"$nulls":4},"Llibres electrònics"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,"Nota di contenuto",null,"Part I Understanding Drug-Induced Lung Injuries -- 1 Understanding Drug-Induced Lung Injuries -- Part 2 Actual Practice in Drug-Induced Lung Injuries of Each Drug -- 2 EGFR inhibitors (gefitinib, erlotinib, afatinib, osimertinib) -- 3 Anti-EGFR antibodies (cetuximab, panitumumab, necitumumab) -- 4 mTOR inhibitors (temsirolimus, everolimus) -- 5 Proteasome inhibitor (bortezomib) -- 6 Immune checkpoint inhibitors (nivolumab, pembrolizumab, atezolizumab, durvalumab) -- 7 Neoangiogenesis inhibitors (sunitinib, sorafenib, bevacizumab) -- 8 Other molecular targeted drugs (crizotinib, alectinib, etc.) -- 9 Antibody-drug conjugates (ADC) (trastuzumab emtansine, trastuzumab deruxtecan) -- 10 Anti-cancer drugs (TS-1, taxanes, CPT-11, platinum-containing drugs, etc.)."]
[null,null,null,"Sommario/riassunto","This book describes the pathologic conditions of drug-induced lung injuries, monitoring strategies, and guides on how to interpret the evidence. It also dives into particular drugs that caused the disorder, such as EGFR inhibitors, anti-EGFR antibodies, mTOR inhibitors, proteasome inhibitors, immune checkpoint inhibitors, neoangiogenesis inhibitors, and other molecular targeted drugs. It outlines the analysis and interpretation of the post-marketing survey on surveillance of each drug for inducing pulmonary lesions presenting diffuse haziness. The data and analysis from this survey are valuable since a guideline is yet to be established due to limited clinical evidence and cases. As new drugs are developed, establishing treatment and event management is crucial. Thus, Drug-induced Pulmonary Disorder in Medical Oncology - Expert Opinion to Decipher Big Data summarizes the accumulated information to provide a foundation for further research advancement. The book offers a refreshing alternative to current approaches to medical oncology and respiratory diseases professionals and will also attract medical affairs members in global pharmaceutical companies."]